Intelligent Bio Solutions Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)3.17 Intrinsic Value No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference. Market Price $1.66Price as of 1 Oct 2026 Data confidence Sign in to view data confidence Market Cap $5.5M Enterprise Value $1.5M Shares Outstanding 3.3M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Intelligent Bio Solutions Inc. (INBS) is a medical technology company pioneering rapid, non-invasive drug screening through fingerprint sweat analysis. The company's razor-razorblade business model is showing strong operational momentum, with cartridge sales driving over 66% of Q3 FY2026 revenue and pushing gross margins past the 50% threshold. However, the company remains highly unprofitable, with a net loss of $2.86 million for the quarter and $7.48 million for the nine months ended March 31, 2026. While its cash position has been temporarily bolstered to $6.86 million through capital raises, the investment case hinges entirely on the successful navigation of the FDA 510(k) regulatory pathway. Given the high volatility, historical dilution, and binary regulatory risk associated with its upcoming U.S. market entry, a Hold recommendation is warranted until FDA clearance is secured. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$12.00 Mean target$12.00 High · most bullish analyst$12.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The FDA requests additional clinical data or identifies deficiencies in the 510(k) submission, delaying U.S. market entry indefinitely. European and APAC sales growth slows down, and the company's cash burn forces further highly dilutive equity raises, depressing the share price. The stock fails to maintain Nasdaq listing requirements, leading to a potential delisting or another reverse stock split. Base CaseCentral scenario The company successfully completes its clinical Cut-off, Interference, and Method Comparison studies by late July 2026. It submits its FDA 510(k) package in late 2026, leading to regulatory clearance and a planned commercial launch in the U.S. market by mid-2027. Revenue continues to grow at a 35-45% annual rate, driven by European and APAC expansion, while gross margins stabilize around 50-52%. Cash burn remains high but manageable with the current runway. Bull CaseUpside scenario Rapidly scaling razor-razorblade model with gross margins crossing 50%, supported by a massive U.S. market entry catalyst upon anticipated FDA 510(k) clearance in H2 2026. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |